title: Effect of phenobarbital administration on theophylline clearance in premature neonates.
abstract: The effect of phenobarbital administration on theophylline clearance was studied in 24 premature neonates. Aminophylline was administered according to a standard protocol of 6 mg/kg loading dose followed by a maintenance dose of 2.5-5 mg/kg/12 h. Of the 24 neonates studied, 12 received a mean phenobarbital dose of 26.34 mg/kg/d (ranging from 2 mg every 24 h to 25 mg every 12 h) and the mean phenobarbital concentration was 56.12 micrograms/ml (range 22-112 micrograms/ml). The remaining 12 patients did not require phenobarbital therapy but did receive aminophylline alone. The two groups were closely matched for gestational age, 5-min Apgar scores, and sex (p greater than 0.2). Steady-state theophylline clearance was determined at least once a week for four or more separate weeks. The study lasted a minimum of 8 wk and if more than one theophylline clearance was determined in any given week, the mean of these clearances was used. Both groups demonstrated an increase in mean theophylline clearance over time (from 15.75 and 16.67 ml/h/kg to 30.33 and 35.42 ml/h/kg for the aminophylline and aminophylline plus phenobarbital groups, respectively). The mean slope, an indicator of the average change in theophylline clearance, was 2.19 for the aminophylline group and 3.27 for the aminophylline plus phenobarbital group (p greater than 0.2), indicating that the theophylline clearance for neonates receiving phenobarbital was not significantly different from that for neonates receiving aminophylline alone. Based on this information, aminophylline does not need to be adjusted solely based on concomitant phenobarbital administration; however, theophylline concentrations should be monitored since theophylline clearance can change rapidly and unpredictably in neonates.
authors.affiliation: Greensboro Area Health Education Center, North Carolina.
authors.forename: R J
authors.initials: RJ
authors.lastname: Kandrotas
authors.forename: T L
authors.initials: TL
authors.lastname: Cranfield
authors.forename: P
authors.initials: P
authors.lastname: Gal
authors.forename: J L
authors.initials: JL
authors.lastname: Ransom
authors.forename: R L
authors.initials: RL
authors.lastname: Weaver
mesh_terms: D003422:Critical Care; D004347:Drug Interactions; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature / Q000378:metabolism*; D008297:Male; D010634:Phenobarbital / Q000494:pharmacology*; D013806:Theophylline / Q000493:pharmacokinetics*
chemical_list: D013806:Theophylline; D010634:Phenobarbital